# Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities

> **NCT05592912** · PHASE1 · WITHDRAWN · sponsor: **PromiSight, LLC**

## Conditions studied

- Pars Plana Vitrectomy

## Interventions

- **DRUG:** HydroLenz Injection
- **OTHER:** No HydroLenz Injection

## Key facts

- **NCT ID:** NCT05592912
- **Lead sponsor:** PromiSight, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding Limitations
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05592912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05592912, "Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05592912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*